Sign in

You're signed outSign in or to get full access.

Crypto Vericonda

Vice President and Senior Equity Analyst at True Securities

Crypto Vericonda is a Vice President and Senior Equity Analyst at True Securities, specializing in research and analysis within the blockchain and fintech sectors. He covers key companies including Coinbase, Ripple, Block, and Chainalysis, maintaining a success rate of 68% and ranking among the top 5% of analysts on TipRanks with average annual investment returns exceeding 12%. Vericonda began his analyst career in 2014 with Oppenheimer & Co., transitioned to Morgan Stanley in 2017, and joined True Securities in early 2021 to lead digital asset coverage. He holds Series 7 and Series 63 licenses and is registered with FINRA, recognized for his thought leadership in crypto market trends and consistently outperforming sector benchmarks.

Crypto Vericonda's questions to INCYTE (INCY) leadership

Question · Q3 2025

Crypto Vericonda asked about the rationale for developing a 989 Ruxolitinib combination in both suboptimal responders and Ruxolitinib-naive patients, or if focusing on one would be a better long-term strategy. He also inquired about FDA guidance for 989 endpoints, specifically if SVR35 and TSS50 would be co-primary endpoints and if both must be hit.

Answer

President Pablo Cagnoni stated that decisions on specific pivotal trials for MF are being made, with updates in early 2026. He confirmed the intent to develop 989 to address all mutant CALR-positive MF patients, including naive and Jakafi-treated (suboptimal/intolerant), where both monotherapy and combination with ruxolitinib could play a role. Regarding FDA guidance, he mentioned ongoing discussions for this novel treatment paradigm, believing it will be based predominantly on clinical endpoints. He suggested there's an argument for modifying previous co-primary endpoints (SVR35 and TSS50) and that impact on anemia could be important for the FDA.

Ask follow-up questions

Fintool

Fintool can predict INCYTE logo INCY's earnings beat/miss a week before the call